The polycythemia vera treatment market is entering a critical phase of change, driven by patent expirations, competitive product launches, and evolving clinical guidelines. For years, JAKAFI (ruxolitinib) has dominated as the standard of care in patients with polycythemia vera who are resistant or intolerant to hydroxyurea. However, as its exclusivity nears an end, the timing of generic entry...